Title |
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
|
---|---|
Published in |
Journal of Inflammation, August 2010
|
DOI | 10.1186/1476-9255-7-41 |
Pubmed ID | |
Authors |
Debra M Meyer, Michael I Jesson, Xiong Li, Mollisa M Elrick, Christie L Funckes-Shippy, James D Warner, Cindy J Gross, Martin E Dowty, Shashi K Ramaiah, Jeffrey L Hirsch, Matthew J Saabye, Jennifer L Barks, Nandini Kishore, Dale L Morris |
Abstract |
The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment. These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | <1% |
Brazil | 1 | <1% |
India | 1 | <1% |
Argentina | 1 | <1% |
Spain | 1 | <1% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 210 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 46 | 21% |
Student > Master | 27 | 12% |
Student > Ph. D. Student | 26 | 12% |
Other | 22 | 10% |
Student > Bachelor | 20 | 9% |
Other | 31 | 14% |
Unknown | 45 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 45 | 21% |
Agricultural and Biological Sciences | 40 | 18% |
Biochemistry, Genetics and Molecular Biology | 25 | 12% |
Chemistry | 16 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 14 | 6% |
Other | 20 | 9% |
Unknown | 57 | 26% |